Differentiating genomics companies.
As the value of raw sequence data diminishes, genomics companies are evolving new competencies as providers of information, therapeutic products, or novel technology.
James
R
R
Prelude Technology Investments, Cambridge CB4 5PJ, UK. rob.james@prelude-technology.co.uk
D001709:Biotechnology / Q000191:economics*; D019295:Computational Biology / Q000191:economics*; D004345:Drug Industry / Q000191:economics*; D015894:Genome, Human; D006801:Humans; D007449:Investments / Q000639:trends*